Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Rivian Automotive, Inc. (RIVN) Price & Performance

ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.

Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.

Rivian (RIVN) trades at $17.48, down 3.69% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company continues to post revenue growth, reaching $5.39 billion in 2025, but remains unprofitable with a net loss of $3.65 billion. Recent news highlights a $1.74 billion stock offering for factory expansion, causing dilution concerns but also reflecting growth ambitions.

The outlook hinges on Rivian's ability to scale production and achieve profitability, supported by analyst consensus targets of $20. Key risks include persistent cash burn, competitive pressures, and execution challenges. The stock presents a high-risk, high-reward opportunity for investors betting on the EV maker's long-term growth trajectory.